Identifying Mutations and Optimizing Use of PARP Inhibitors

Cancer Center Symposium 15 May 2018Подробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy | Webinar | Ambry GeneticsПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

The Role of PARP Inhibitors in Advanced Prostate CancerПодробнее

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP InhibitorsПодробнее

Discovering PARP inhibitor resistance with CRISPRПодробнее

The Role of Targeting DNA Repair with PARPПодробнее

2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Webinar: Parp-Inhibitors and Prostate Cancer - Gotta Have a Mutation??? 06/29/2023Подробнее

Where can PARP inhibitors be usedПодробнее

Which mutations benefit most from PARP inhibitors in prostate cancer?Подробнее

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier SettingsПодробнее

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

The Role of Genetic Testing and PARP Inhibitors (2022)Подробнее

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate CancerПодробнее

Targeted cancer therapy: choosing the right assay to assess PARP inhibitorsПодробнее